“Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s177. doi:10.25251/skin.7.supp.177.